Explained: Inside Novo Nordisk’s $9 Billion bid to outmuscle Pfizer
Drug giants Novo Nordisk and Pfizer are locked in a fierce $9 billion bidding war for obesity drug developer Metsera. Novo's unsolicited offer challenges Pfizer's earlier $7.3 billion deal, highlighting the immense value and competition in the booming weight-loss drug market. This corporate showdown could redefine the future of obesity treatment.
Drug giants Novo Nordisk and Pfizer are locked in a fierce $9 billion bidding war for obesity drug developer Metsera. Novo's unsolicited offer challenges Pfizer's earlier $7.3 billion deal, highlighting the immense value and competition in the booming weight-loss drug market. This corporate showdown could redefine the future of obesity treatment.
